Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Solid Cancers 1Sezary Syndrome 1Polycystic Ovary Syndrome 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Follicular 1Central Nervous System Neoplasms 1Alzheimer Disease 1

Interventions

Temozolomide 30Radiotherapy 21Etoposide 9Carboplatin 9Bevacizumab 9Cyclophosphamide 8Vincristine 7Radiation 7Filgrastim 7Cisplatin 7Magnetic Resonance Spectroscopy 6Irinotecan 5Ifosfamide 5Granulocyte Colony-Stimulating Factor 5etoposide phosphate 4X-Rays 4Specimen Handling 4Phantoms, Imaging 4Lomustine 4Everolimus 4selpercatinib 3larotrectinib 3Thalidomide 3Paclitaxel 3Nuclear Medicine Department, Hospital 3Methotrexate 3Erlotinib Hydrochloride 3Chemotherapy, Adjuvant 3Celecoxib 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Central Nervous System Neoplasms × Rosiglitazone × Clear all
NCT00616642 2020-08-14

Rosiglitazone in Treating Patients With Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
1 enrolled 4 charts
CNSEndocrine

Pituitary Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡